These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 12368073)

  • 1. Statins as anti-inflammatory agents.
    Weitz-Schmidt G
    Trends Pharmacol Sci; 2002 Oct; 23(10):482-6. PubMed ID: 12368073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perspectives on the cardioprotective effects of statins.
    Luo JD; Chen AF
    Curr Med Chem; 2003 Aug; 10(16):1593-601. PubMed ID: 12871130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate beta-amyloid-induced microglial inflammatory responses.
    Cordle A; Landreth G
    J Neurosci; 2005 Jan; 25(2):299-307. PubMed ID: 15647473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy.
    Danesh FR; Kanwar YS
    FASEB J; 2004 May; 18(7):805-15. PubMed ID: 15117885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Statins and asthma].
    Pawlak J; Ziętkowski Z; Bodzenta-Łukaszyk A
    Postepy Hig Med Dosw (Online); 2011 Mar; 65():177-89. PubMed ID: 21502694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase the binding activity and nuclear level of Oct-1 in mononuclear cells.
    Ortego M; Hernández AG; Bustos C; Blanco-Colio LM; Hernández-Presa MA; Tuñón J; Egido J
    Eur J Pharmacol; 2002 Jul; 448(2-3):113-21. PubMed ID: 12144930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HMG-CoA reductase inhibition: anti-inflammatory effects beyond lipid lowering?
    März W; Köenig W
    J Cardiovasc Risk; 2003 Jun; 10(3):169-79. PubMed ID: 12775949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors.
    Kiener PA; Davis PM; Murray JL; Youssef S; Rankin BM; Kowala M
    Int Immunopharmacol; 2001 Jan; 1(1):105-18. PubMed ID: 11367508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statins: the new aspirin?
    Veillard NR; Mach F
    Cell Mol Life Sci; 2002 Nov; 59(11):1771-86. PubMed ID: 12530513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions.
    Mason RP; Walter MF; Day CA; Jacob RF
    Am J Cardiol; 2005 Sep; 96(5A):11F-23F. PubMed ID: 16126019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
    Moghadasian MH
    Life Sci; 1999; 65(13):1329-37. PubMed ID: 10503952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotropic Effects and Proposed Mechanism of Action for 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase Inhibitors (Statins).
    Arefieva TI; Filatova AY; Potekhina AV; Shchinova AM
    Biochemistry (Mosc); 2018 Aug; 83(8):874-889. PubMed ID: 30208827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statin therapy-evidence beyond lipid lowering contributing to plaque stability.
    de Lorenzo F; Feher M; Martin J; Collot-Teixeira S; Dotsenko O; McGregor JL
    Curr Med Chem; 2006; 13(28):3385-93. PubMed ID: 17168712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3-hydroxy-3-methylglutaryl coenzyme A reductase-independent inhibition of CD40 expression by atorvastatin in human endothelial cells.
    Wagner AH; Gebauer M; Güldenzoph B; Hecker M
    Arterioscler Thromb Vasc Biol; 2002 Nov; 22(11):1784-9. PubMed ID: 12426205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results.
    Wang CY; Liu PY; Liao JK
    Trends Mol Med; 2008 Jan; 14(1):37-44. PubMed ID: 18068482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-talk between exogenous statins and endogenous high-density lipoprotein in anti-inflammatory and anti-atherogenic actions.
    Kimura T; Sato K; Tomura H; Okajima F
    Endocr Metab Immune Disord Drug Targets; 2010 Mar; 10(1):8-15. PubMed ID: 20105136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer.
    Graaf MR; Richel DJ; van Noorden CJ; Guchelaar HJ
    Cancer Treat Rev; 2004 Nov; 30(7):609-41. PubMed ID: 15531395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct vascular effects of HMG-CoA reductase inhibitors.
    Bellosta S; Bernini F; Ferri N; Quarato P; Canavesi M; Arnaboldi L; Fumagalli R; Paoletti R; Corsini A
    Atherosclerosis; 1998 Apr; 137 Suppl():S101-9. PubMed ID: 9694549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases?
    McCarey DW; Sattar N; McInnes IB
    Arthritis Res Ther; 2005; 7(2):55-61. PubMed ID: 15743490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One statin, two statins, three statins, more: similarities and differences of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
    Turkoski BB
    Orthop Nurs; 2011; 30(1):62-5; quiz 66-7. PubMed ID: 21278557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.